Interferon Treatment Improves Survival among Liver Transplant Recipients with Recurrent Hepatitis C
Journal Title: Journal of Surgery - Year 2013, Vol 1, Issue 1
Abstract
Hepatitis C in the liver allograft recipient has an aggressive course. A significant proportion of such recipients develop graft fibrosis and cirrhosis within five years of transplantation. Treatment efficacy with standard or pegylated interferon and ribavirin is suboptimal compared to the immunocompetent individuals. However, the effect of such therapy on graft and patient survival remains unknown. Objectives: To determine the efficacy of interferon based therapies in liver transplantation recipients with recurrent hepatitis C, and to determine the effect of interferon treatment on graft and patient survival. Methods: We retrospectively analyzed 823 hepatitis C patients, who underwent liver transplantation at Thomas E Starzl Transplantation Institute, University of Pittsburgh between January 1992 and April 2006. Two hundred and sixty four patients received either interferon (all kinds) monotherapy, or combination therapy. The primary end point was graft failure and death. Results: Both treated and untreated groups were similar in clinical characteristics at the time of transplantation. In treatment group, 77% received prednisone based immunosuppression as compared to 75% in no treatment group. 57% of patients in treatment group had HCV RNA >1 million units/ml after transplantation. Patients were categorized into four groups; no treatment (n=440), ≤ 24 weeks of treatment (n=38), 25-48 weeks of treatment (n=64) and >48 weeks of treatment (162). Total bilirubin > 2 at 6 and 12 months and an AST/ALT ratio of >1 at 6 month of transplantation are independently associated with poor patient survival. Patients who received treatment for >48 weeks have significantly improved survival independent of sustained viral response (HR 0.33, p=< 0.001). Conclusion: Among liver transplant recipients with recurrent hepatitis C, treatment with any interferon with or without ribavirin for >48 weeks is significantly associated with improved patient survival regardless of viral response. Prospective trials are indicated to confirm these findings.
Authors and Affiliations
Shahid Habib
Keywords
Related Articles
- EP ID EP203756
- DOI 10.13188/2332-4139.1000007
- Views 131
- Downloads 0
Effect and Molecular Mechanism of Wnt/β-Catenin Signaling Pathway on Apoptosis after Spinal Cord Injury
Secondary injury plays a more important role in the development of spinal cord injury (SCI), mainly due to apoptosis, inflammatory response, oxidative stress and other causes, especially neuronal cell apoptosis inhibits...
Epidermal Inclusion Cyst of the Breast
Epidermal inclusion cysts are uncommon in the breast, but theconsequences can be severe when these cysts occur in the breastparenchyma. Here we report one such case. The patient was 45 years old women with 3*2 cms mobile...
The Role of Prophylactic Lymph Node Dissection in Patients with Intrahepatic Cholangiocarcinoma
Purpose: We investigated the role of prophylactic lymph node dissection (LND) in patients with intrahepatic cholangiocarcinoma (ICC). Methods: A retrospective analysis was performed evaluating the impact on survival of...
Laparoscopic vs Open Excision of Urachal Remnants in Children
Introduction: A urachal remnant forms when the allantois fails to completely obliterate. This results in a spectrum of anomalies. It is generally accepted that urachal remnants should be excised. Traditionally, excision...
Splenopathy in Patients with Sickle Cell Disease
Splenopathy with sickle cell disease refers to disorders that require medical care and surgical treatment. It is common in patients with sickle cell disease. The genotype of patients with sickle cell disease could affect...